Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSC:2196 Stock Report

Market Cap: HK$68.4b

Shanghai Fosun Pharmaceutical (Group) Management

Management criteria checks 2/4

Shanghai Fosun Pharmaceutical (Group)'s CEO is Deyong Wen, appointed in Jan 2022, has a tenure of 2.83 years. total yearly compensation is CN¥10.00M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth HK$2.67M. The average tenure of the management team and the board of directors is 2.1 years and 3.4 years respectively.

Key information

Deyong Wen

Chief executive officer

CN¥10.0m

Total compensation

CEO salary percentage25.9%
CEO tenure2.8yrs
CEO ownership0.004%
Management average tenure2.1yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deyong Wen's remuneration changed compared to Shanghai Fosun Pharmaceutical (Group)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥10mCN¥3m

CN¥2b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥8mCN¥2m

CN¥4b

Compensation vs Market: Deyong's total compensation ($USD1.38M) is above average for companies of similar size in the Hong Kong market ($USD899.89K).

Compensation vs Earnings: Deyong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Deyong Wen (53 yo)

2.8yrs

Tenure

CN¥9,997,000

Compensation

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman2.9yrsCN¥15.25m0.012%
HK$ 8.4m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.045%
HK$ 31.1m
Deyong Wen
Joint President2.8yrsCN¥10.00m0.0039%
HK$ 2.7m
Xiaohui Guan
Executive Vice Chairman2.9yrsCN¥9.14m0.011%
HK$ 7.6m
Rongli Feng
Executive President & Chief Human Resources Officeless than a yearno data0.0043%
HK$ 2.9m
Jing Li
Executive President and CEO of Established Medicines Manufacturing & Supply Divisionno datano data0.0043%
HK$ 2.9m
Wang Xingli
Executive President1.8yrsno datano data
Wenjie Zhang
Executive President & Co-CEO of Innovative Drug Division1.8yrsno datano data
Zhanyu Chen
Senior VP & CFOless than a yearno datano data
Jia Yan
Director of the Accounting Departmentno datano datano data
Dongjiu Li
Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee3.7yrsno data0.0025%
HK$ 1.7m
Donghua Wang
Senior VP & Chief Strategic Enabler4.1yrsno data0.0043%
HK$ 2.9m

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 2196's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kexin Wang
Executive Co-Chairman2.9yrsCN¥15.25m0.012%
HK$ 8.4m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.045%
HK$ 31.1m
Deyong Wen
Joint President2.3yrsCN¥10.00m0.0039%
HK$ 2.7m
Xiaohui Guan
Executive Vice Chairman2.9yrsCN¥9.14m0.011%
HK$ 7.6m
Guliang Tang
Independent Non-Executive Director5.4yrsCN¥392.00kno data
Qiyu Chen
Non-Executive Director19.5yrsno data0.0043%
HK$ 2.9m
Xiaoliang Xu
Non-Executive Director5.4yrsno datano data
Ling Li
Independent Non-Executive Director5.4yrsCN¥392.00kno data
Tze Shan Yu
Independent Non-Executive Director3.4yrsCN¥392.00kno data
Yuqing Chen
Non-Executive Directorless than a yearno data0.0058%
HK$ 4.0m
Quandi Wang
Independent Non-Executive Director3.4yrsCN¥392.00kno data
Bing Chen
Chief Supervisor1.4yrsno datano data

3.4yrs

Average Tenure

54yo

Average Age

Experienced Board: 2196's board of directors are considered experienced (3.4 years average tenure).